Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD	non-small cell lung carcinoma	Recruiting	Not applicable	2025-10-02		NCT06924710

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Friendship Hospital	120
Bethune First Hospital of Jilin University	1
Geneplus-Beijing Co. Ltd.	10
Liaoning Cancer Hospital & Institute	53
Peking University Cancer Hospital & Institute	189
Peking University First Hospital	225
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	141
Tianjin Chest Hospital	12

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Peking University Cancer Hospital & Institute	Beijing	China	14